-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Sponsor: an educational grant from Genmab US, Inc. and AbbVie
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies, Adverse Events, Biological Processes
Friday, December 8, 2023: 3:00 PM-6:00 PM
Room 30 A-E (San Diego Convention Center)
Chair:
Joshua Brody, MD, Icahn School of Medicine at Mount Sinai
Disclosures:
Brody: Kite Pharma: Research Funding; Merck: Research Funding; Genentech: Research Funding; SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite: Consultancy; Kite-Gilead: Research Funding; SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite: Research Funding.
Speakers:
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center and Lori A. Leslie, MD, Hackensack Meridian School of Medicine
Disclosures:
Falchi: Genmab: Consultancy, Honoraria, Other: Travel reimbursement, Research Funding; AstraZeneca: Other: Advisory board; Ipsen: Other: Advisory board; Evolveimmune: Consultancy; Innate Pharma: Research Funding; Abbvie: Consultancy, Honoraria, Other: Advisory Board, travel reimbursement, Research Funding; Genentech: Consultancy, Honoraria, Other: Advisory Board, Research Funding; Roche: Consultancy, Research Funding; Seagen: Other: Advisory Board; ADC Therapeutics: Other: Advisory Board. Leslie: Eli Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Kite, a Gilead Company: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Janssen/ J&J: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astrazeneca: Consultancy, Other: Travel support, Speakers Bureau; Beigene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; SeaGen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene/ Bristol Myers Squibb: Other: Travel support, Speakers Bureau; Janssen/PCYC: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; LLS: Other: Educational role/ Leadership role in LLS light the night events (unpaid); LRF: Other: Educational role; CLL: Other: Educational role; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees.
Access Program Details

This activity is intended to educate clinicians regarding the use and integration of new and emerging BCMA-targeted therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In the “Care Team Forum,” an expert panel will present 3 series of didactic slides, followed by discussion that will include a patient with R/R DLBCL; they will share key aspects of their therapeutic journey. Polling questions will be interspersed throughout the symposium to assess improvements in knowledge and competence among attendees.